Answers are grounded in this paper and cite their sources.
Our expanding knowledge of the immune system is guiding a new era of targeted anticancer therapies. Here, we describe our recent work on a novel class of anticancer agents termed ImmTACs. These molecules combine the power of picomolar-affinity TCR-based antigen recognition with the immune-activating potential of an anti-CD3 antibody fragment, to potently redirect T-cell killing to tumor cells.
No takes yet. Share an insight, caveat, or question.
Oates et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: